The pharmaceutical company AI-Therapeutics (Guilford, CT, USA) has acquired the preclinical drug candidates EC-8042 and EC-70124 in the course of the insolvency proceedings EntreChem was experiencing since February of last... read more →
Rhabdoid tumor is a pediatric cancer characterized by the biallelic inactivation of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. SMARCB1 inactivation leads to SWI/SNF redistribution to favor... read more →
EntreChem, 2 European Universities and Novartis to cooperate in the project "MISSION: Streamlined Streptomyces cell factories for industrial production of valuable natural products." The European Commission has awarded €1.8M... read more →
Acute Myeloid Leukemia (AML) is the most common myeloid malignancy in adults, and Internal Tandem Duplication (ITD) or kinase domain mutation of FLT3 represent the most frequent genetic alteration,... read more →
Sarcoma models derived from human mesenchymal stromal/stem cells (hMSCs) are used to understand better the initiation of sarcomagenesis, not amenable to analysis in patient samples or cell lines. This study... read more →
The fusion protein EWS-FLI1 is a constitutively activated transcription factor responsible for the oncogenic phenotype of Ewing sarcoma (EWS). Mithramycin is a potent inhibitor of EWS-FLI1, but its toxicity makes... read more →
Cancer stem cells (CSCs) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance to current therapies. The transcription factors NF-κB and STAT3 are frequently... read more →
Activated kinases were identified by using phosphokinase arrays with human colorectal tumor samples, including the Epidermal Growth Factor Receptor (EGFR), components of the PI3K/mTOR pathway (AKT and S6), and SRC,... read more →
EC-70124, a kinase inhibitor, shows in vitro and in vivo antiproliferative effects mediated by simultaneous inhibition of the PI3K/mTOR y JAK/STAT signaling pathways and also DNA damage induction, causing cell... read more →
EntreChem and three Universities from three European countries to cooperate in the project. The European Commission has awarded €1 million to the ERA-IB project "NeBrasCa - Next Generation Immunosuppressants: Brasilicardin... read more →
